Suchergebnisse - "Cook, Gordon"

PubPharm (26)

1

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Kaiser, M. | Hall, A. | Walker, K. | +17

2

The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages : results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial

enthalten in: British journal of haematology | 2023

von Jenner, M. | Pawlyn, C. | Davies, F. | +16

3

Optimizing the value of lenalidomide maintenance by extended genetic profiling : an analysis of 556 patients in the Myeloma XI trial

enthalten in: Blood | 2023

von Panopoulou, A. | Cairns, D. | Holroyd, A. | +13

CommentIn: Blood. 2023 Apr 6;141(14):1649-1650. - PMID 37022733

4

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma : Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von de Tute, R. | Pawlyn, C. | Cairns, D. | +14

CommentIn: J Clin Oncol. 2022 Sep 1;40(25):2863-2866. - PMID 35772041

5

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)) : a study protocol for a randomised phase III trial

enthalten in: BMJ open | 2022

von Coulson, A. | Royle, K. | Pawlyn, C. | +22

CommentIn: Lancet Healthy Longev. 2022 Nov;3(11):e729-e730. - PMID 36356621

6

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma : frailty subgroup analysis of MAIA

enthalten in: Leukemia | 2022

von Facon, T. | Cook, G. | Usmani, S. | +25

7

Ixazomib-lenalidomide-dexamethasone in routine clinical practice : effectiveness in relapsed/refractory multiple myeloma

enthalten in: Future oncology (London, England) | 2021

von Hájek, R. | Minařík, J. | Straub, J. | +33

8

Health-related quality of life in patients with relapsed or refractory multiple myeloma : treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial

enthalten in: British journal of haematology | 2021

von Plesner, T. | Dimopoulos, M. | Oriol, A. | +15

9

Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial

enthalten in: Haematologica | 2021

von Jackson, G. | Davies, F. | Pawlyn, C. | +21

10

Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial

enthalten in: Leukemia | 2021

von Croft, J. | Ellis, S. | Sherborne, A. | +19